Founded with the mission to revolutionize surgical procedures, Amsel Medical focuses on developing innovative mechanical surgical clamping technology. Their flagship product, the SCureClamp with Interdigitation Occlusion Technology (iDOT™), is designed to securely close vessels such as veins, arteries, and tubular structures during surgical and interventional procedures. This technology aims to enhance the precision and safety of vessel occlusion, catering to a broad range of surgical needs.
Amsel Medical's SCureClamp has received both CE mark and FDA clearance, underscoring its compliance with rigorous international standards. The company has garnered attention for its minimally invasive approach, delivering the clamp through an 18 G needle. This innovation has the potential to significantly impact surgical outcomes by reducing complications associated with vessel closure. The company's leadership and investor details are not publicly disclosed, but their achievements in regulatory approvals highlight their commitment to advancing medical technology.
